Categories Cancer

Study finds significant variation in biomarker test utilization and treatment for non–small-cell lung …

Study finds significant variation in biomarker test utilization and treatment for non–small-cell lung … Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC). In a new study in The Journal of Molecular Diagnosis, published by Elsevier, investigators provide for […]

Read More
Categories Cancer

Covid: Charities warn cancer death rate could rise

Covid: Charities warn cancer death rate could rise Contributors A group of 47 cancer charities says that without urgent action, the UK’s cancer death rate will rise for the first time in decades. NHS figures suggest tens of thousands fewer people started cancer treatment since the first lockdown compared to normal times. One Cancer Voice […]

Read More
Categories Uncategorized

NCCN Updates Clinical Practice Guideline for Multiple Myeloma

NCCN Updates Clinical Practice Guideline for Multiple Myeloma On March 15, 2021, the National Comprehensive Cancer Network (NCCN) released an update to its clinical practice guideline for multiple myeloma. In the section for therapy for previously treated multiple myeloma, under other regimens, melphalan flufenamide/dexamethasone was added as a category 2A recommendation.—Janelle Bradley Published at Tue, […]

Read More
Categories Multiple Myeloma

Zacks: Analysts Expect Fate Therapeutics, Inc. (NASDAQ:FATE) Will Post Quarterly Sales of $7.07 …

Zacks: Analysts Expect Fate Therapeutics, Inc. (NASDAQ:FATE) Will Post Quarterly Sales of $7.07 … Wall Street analysts expect Fate Therapeutics, Inc. (NASDAQ:FATE) to report $7.07 million in sales for the current quarter, according to Zacks Investment Research. Eight analysts have issued estimates for Fate Therapeutics’ earnings. The lowest sales estimate is $5.00 million and the […]

Read More
Categories Cancer

Eisai’s anti-cancer agent LENVIMA receives orphan drug designation

Eisai’s anti-cancer agent LENVIMA receives orphan drug designation Japanese pharmaceutical company Eisai has received orphan drug designation for its anti-cancer agent LENVIMA with a prospective indication for uterine body cancer. LENVIMA, which obtained the designation from the Ministry of Health, Labour and Welfare (MHLW), is an orally available multiple receptor kinase inhibitor discovered by Eisai. […]

Read More
Categories Cancer

Don’t Delay: Patients With Cancer Need Both Doses of COVID Vax

Don’t Delay: Patients With Cancer Need Both Doses of COVID Vax Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The first report on responses to COVID-19 vaccination among patients with cancer suggests that for these patients, the immune response that occurs after the first dose of vaccine is reduced […]

Read More
Categories Multiple Myeloma

Bromodomain Testis Specific Protein Market 2021 Complete Data Analysis

Bromodomain Testis Specific Protein Market 2021 Complete Data Analysis Global Bromodomain Testis Specific Protein Market Overview: Global Bromodomain Testis Specific Protein Market presents insights on the current and future industry trends, enabling the readers to identify the products and services, hence driving the revenue growth and profitability. The research report provides a detailed analysis of […]

Read More
Categories Multiple Myeloma

NEWS FEATURE | Ultimate pain killer: doctor with cancer fights to the death for assisted suicide

NEWS FEATURE | Ultimate pain killer: doctor with cancer fights to the death for assisted suicide Palliative care specialist uses her years caring for terminal patients and her own experience of cancer to strengthen her case 15 March 2021 – 19:54 On February 3 2017, palliative care specialist Dr Sue Walter was driving in Joburg […]

Read More